

Editas Medicine Inc (EDIT) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/E55B721B86DEN.html>

Date: June 2021

Pages: 52

Price: US\$ 125.00 (Single User License)

ID: E55B721B86DEN

Abstracts

Editas Medicine Inc (EDIT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Editas Medicine Inc (Editas Medicine) formerly Gengine Inc, is a clinical stage biotechnology company that develops genome treatments for rare diseases. The company is developing a proprietary genome editing platform based on its in-licensed clustered regularly interspaced short palindromic repeats (CRISPR) technology. The company's pre-clinical pipeline spans investigational candidates for the treatment of ocular and blood diseases, cancer, and diseases of other organs and tissues. The company works in collaboration with Allergan/ AbbVie Inc, AskBio, Bayer AG, BlueRock Therapeutics, The Broad Institute Inc, Massachusetts Institute of Technology, Harvard Institute, The Rockefeller University, Celgene Corp and Bristol Myers Squibb to discover and develop its pipeline products. Editas Medicine is headquartered in Cambridge, Massachusetts, the US.

Editas Medicine Inc Key Recent Developments

Jun 15,2021: Editas Medicine Reports Inducement Grants to New Chief Scientific Officer and Chief Regulatory Officer

Jun 14,2021: Editas Medicine Strengthens Executive Leadership Team to Advance Pipeline and Support Long-term Growth

May 05,2021: Editas Medicine Announces First Quarter 2021 Results and Update

May 05,2021: Editas Medicine Names Mark S. Shearman, Ph.D., As Chief Scientific Officer

Apr 28,2021: Editas Medicine to Host Conference Call Discussing First Quarter 2021 Results and Corporate Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Editas Medicine Inc - Key Facts
Editas Medicine Inc - Key Employees
Editas Medicine Inc - Key Employee Biographies
Editas Medicine Inc - Major Products and Services
Editas Medicine Inc - History
Editas Medicine Inc - Company Statement
Editas Medicine Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Editas Medicine Inc - Business Description
Editas Medicine Inc - Corporate Strategy
Editas Medicine Inc - SWOT Analysis
SWOT Analysis - Overview
Editas Medicine Inc - Strengths
Editas Medicine Inc - Weaknesses
Editas Medicine Inc - Opportunities
Editas Medicine Inc - Threats
Editas Medicine Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCENCES FINANCIAL DEALS AND ALLIANCES

Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Editas Medicine Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jun 15, 2021: Editas Medicine Reports Inducement Grants to New Chief Scientific Officer and Chief Regulatory Officer

Jun 14, 2021: Editas Medicine Strengthens Executive Leadership Team to Advance Pipeline and Support Long-term Growth

May 05, 2021: Editas Medicine Announces First Quarter 2021 Results and Update

May 05, 2021: Editas Medicine Names Mark S. Shearman, Ph.D., As Chief Scientific Officer

Apr 28, 2021: Editas Medicine to Host Conference Call Discussing First Quarter 2021 Results and Corporate Update

Feb 25, 2021: Editas Medicine announces fourth quarter and full year 2020 results and update

Feb 18, 2021: Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2020 Results and Corporate Update

Feb 18, 2021: February 18, 2021 Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2020 Results and Corporate Update

Feb 08, 2021: Editas Medicine Announces Appointment of James C. Mullen as Chief Executive Officer

Jan 11, 2021: Editas Medicine announces transition of chief scientific officer

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Editas Medicine Inc, Key Facts
Editas Medicine Inc, Key Employees
Editas Medicine Inc, Key Employee Biographies
Editas Medicine Inc, Major Products and Services
Editas Medicine Inc, History
Editas Medicine Inc, Subsidiaries
Editas Medicine Inc, Key Competitors
Editas Medicine Inc, Ratios based on current share price
Editas Medicine Inc, Annual Ratios
Editas Medicine Inc, Annual Ratios (Cont...1)
Editas Medicine Inc, Interim Ratios
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Editas Medicine Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Editas Medicine Inc, Performance Chart (2016 - 2020)

Editas Medicine Inc, Ratio Charts

Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Editas Medicine Inc (EDIT) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/E55B721B86DEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E55B721B86DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970